

DETAILED ACTION

Declaration of Richard Todebush filed on 03/22/2004 has been fully considered by the Examiner.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Warren D. Schickli on 2/28/08.

The application has been amended as follows:

IN THE CLAIMS:

- Claim 1 has been amended to read:

A process for preparing gabapentin tannate to be used in a pharmaceutical composition, said process comprising: reacting gabapentin with tannic acid.

- Claim 4 has been amended to read:

The process of claim 1 including providing gabapentin tannate in liquid or semi-solid dosage forms.

- Claim 5 has been amended to read:

The process of claim 1 including providing gabapentin tannate in suspension dosage form.

- Claim 6 has been amended to read:

A process for preparing gabapentin tannate to be used in a pharmaceutical composition, said process comprising:

mixing tannic acid and a dispersing agent in a solvent to obtain a dispersion; and adding gabapentin to the said dispersion.

- Claim 20 has been amended to read:

A composition comprising gabapentin tannate.

- Claim 30 has been canceled.

- Claim 31 has been canceled.

- Claim 32 has been canceled.

- Claim 33 has been amended to read:

A process for preparing gabapentin tannate to be used in a pharmaceutical composition, said process comprising:

(i) reacting gabapentin with tannic acid to produce gabapentin tannate; and

Art Unit: 1621

(ii) directly incorporating the gabapentin tannate into a suitable pharmaceutical suspension dosage form without further purification and isolation.

/YVONNE L. EYLER/

Supervisory Patent Examiner, Art Unit 1621